MTV News has learned that the makers of the first generation of interferon are still waiting to make a final decision on whether to approve a second generation of the drug, which was first approved in 2008.
“Interferon 2 and 3 are a great first generation product,” said Dr. Eric G. Wertheim, a professor of preventive medicine at the Yale School of Medicine and co-director of the Yale Interferons Center.
“We’re seeing more and more clinical benefit, and I think we need to take it a step further in order to have a longer-term, well-designed clinical trial.”
The drug, first approved by the Food and Drug Administration in 2007, is the first of two new versions of the highly effective drug, known as T-2a, that have been approved by doctors and the FDA.
The new version of the T-1a version is being marketed as the “preventative” version of T-3a, which is being phased out.
Interferone has been on the market since 1999, and the drug is considered to be safe and effective.
Gansner says that the FDA has been “very cautious” about the T2a version, but that the T1a drug is also in good health.
Interval trial The FDA says that its trial is continuing to evaluate T2 and T1 a versions of InterferON, and is expected to be finished by the end of March.
The Interferona company says that Ganser is a professor at Yale and the co-author of a paper on the drug.
Gannes, who co-founded the Yale interferons center, says that he was invited to speak at a meeting in the fall of 2012 to discuss the Interferones safety and effectiveness.
GANGSER: It’s a real honor to be invited by the Interferenx team to talk about their product.
But it’s not my company’s job to speak for them.
We’re talking to our own research, and we have a very good relationship with the InterFERON team.
Interferences are a topic that has been discussed in the media recently, as doctors have been urging the FDA to approve T-4a and T-5a interferonal drugs as a way to prevent complications in those with cardiovascular disease.
In addition, doctors have urged the FDA not to approve the first T-6a version of Interfereon, because it might be less effective than the first version, which has been proven to reduce complications in people with heart disease.
“The drug will be ready to market by March,” Gannesian said.
“But they don’t have a date yet.
They’re still waiting.”
“It’s a very complicated problem,” he said.
It’s difficult to know how much benefit there might be from taking the new drug, and whether the drugs will have any long-term effects, Ganneson said.
Some studies have shown that T2A is more effective than T2b in reducing cardiovascular events, but it is not yet clear whether the T3a version could have more long-lasting benefits than T1b.
It is not clear whether T3b might have a lower risk of developing cardiovascular disease than T4a or T5a.